Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 26 (3), 259-64

Biomarkers in Prostate Cancer: What's New?

Affiliations
Review

Biomarkers in Prostate Cancer: What's New?

David A Sartori et al. Curr Opin Oncol.

Abstract

Purpose of review: This review is intended to provide an overview of the current state of biomarkers for prostate cancer (PCa), with a focus on biomarkers approved by the US Food and Drug Administration (FDA) as well as biomarkers available from Clinical Laboratory Improvement Amendment (CLIA)-certified clinical laboratories within the last 1-2 years.

Recent findings: During the past 2 years, two biomarkers have been approved by the US FDA. These include proPSA as part of the Prostate Health Index (phi) by Beckman Coulter, Inc and PCA3 as Progensa by Gen Probe, Inc. With the advances in genomic and proteomic technologies, several new CLIA-based laboratory-developed tests have become available. Examples are Oncotype DX from Genomics Health, Inc, and Prolaris from Myriad Genetics, Inc. In most cases, these new tests are based on a combination of multiple genomic or proteomic biomarkers.

Summary: Several new tests, as discussed in this review, have become available during the last 2 years. Although the intended use of most of these tests is to distinguish PCa from benign prostatic conditions with better sensitivity and specificity than prostate-specific antigen, studies have shown that some of them may also be useful in the differentiation of aggressive from nonaggressive forms of PCa.

Conflict of interest statement

Conflicts of interest

Daniel Chan is currently receiving grants from the National Cancer Institute EDRN and CPTAC programs. For the remaining author none are declared. The authors have no conflicts of interest to disclose.

Similar articles

See all similar articles

Cited by 44 PubMed Central articles

See all "Cited by" articles
Feedback